Biotech Series B Investors & VC Firms

724 firms in this list, with a median first check of $500K. 165 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
CO Coinvest Capital VTEŽKJAL9 people	88🔒	Vilnius	LT	Pre-Seed–Growth	$55K – $580K	+ Add to CRM
PA Panakes Partners ABFLLBMS14 people · Follows rounds	88🔒	Milan	IT	Seed–Growth	—	+ Add to CRM
NE New Rhein Healthcare Investors, LLC NGIGSSAA15 people	88🔒	Philadelphia	US	Series B–Late Stage	—	+ Add to CRM
HI Hikma Ventures LGAFSAAA13 people · Leads rounds	88🔒	London	GB	Seed–Growth	$5M	+ Add to CRM
IN iNetworks AMAJGMJ11 people	88🔒	Pittsburgh	US	Seed–Late Stage	—	+ Add to CRM
HA Harmonix Fund CMDMEPMW7 people	88🔒	La Quinta	US	Seed–Series C	—	+ Add to CRM
HI Hillhouse Capital TKBWDLHW7 people · Leads rounds	88🔒	Changyang	CN	Seed–Series C	$500K	+ Add to CRM
MI Mithril Capital Management PTARAKAR5 people · Follows rounds	88🔒	Austin	US	Series B–Late Stage	—	+ Add to CRM
VA Valspring Capital AZASYCCL8 people · Leads rounds	88🔒	Boston	US	Series A–Growth	—	+ Add to CRM
PU Pureos Bioventures DEKBMMVG9 people	88🔒	Pfäffikon	CH	Seed–Series C	—	+ Add to CRM
CU Cultivian Sandbox Ventures AZBSDPNR8 people · Follows rounds	88🔒	Chicago	US	Seed–Late Stage	$5M – $15M	+ Add to CRM
SA Santen Pharmaceutical HIIKJAMP24 people	88🔒	Osaka	JP	Series A–Series C	—	+ Add to CRM
RO Roche Venture Fund MSAHCCBF7 people	88🔒	Basel	CH	Seed–Growth	$648K – $3.2M	+ Add to CRM
HE Heran Partners AVHVJMKV13 people	88🔒	Antwerp	BE	Seed–Series B	—	+ Add to CRM
IS ISA Ventures FCCGEESG4 people	88🔒	Cedar Rapids	US	Pre-Seed–Late Stage	$25K – $1M	+ Add to CRM
FA Fast Track Initiative NRKY2 people	88🔒	Tokyo	JP	Pre-Seed–Growth	—	+ Add to CRM
LE Leaps by Bayer BKDDDNPA6 people	88🔒	Leverkusen	DE	Seed–Growth	—	+ Add to CRM
VI Visionary Ventures GHDGPSBC9 people	88🔒	Newport Beach	US	Series A–Growth	$5M – $15M	+ Add to CRM
FI Fine Structures Ventures AJCDDNDM10 people	88🔒	Cambridge	US	Pre-Seed–Late Stage	—	+ Add to CRM
RE Redesign Health NGPAAGMK13 people	88🔒	New York	US	Seed–Late Stage	—	+ Add to CRM
LU Luma Group JFTKJKNM14 people	88🔒	New York	US	Seed–Growth	—	+ Add to CRM
TR Triatomic Capital JHPZSHWV8 people · Leads rounds	88🔒	Palo Alto	US	Seed–Series C	$100K – $1M	+ Add to CRM
ES Esplanade Ventures SESMESAN10 people · Leads rounds	88🔒	Toronto	CA	Seed–Series B	—	+ Add to CRM
YU Yuanta Investment 강강김김20 people	88🔒	Seoul	KR	Seed–Late Stage	$1M – $15M	+ Add to CRM

Coinvest Capital

VilniusPre-Seed–Growth$55K – $580K

VTEŽKJAL9 people

Panakes Partners

MilanSeed–Growth

ABFLLBMS14 people

New Rhein Healthcare Investors, LLC

PhiladelphiaSeries B–Late Stage

NGIGSSAA15 people

Hikma Ventures

LondonSeed–Growth$5M

LGAFSAAA13 people

iNetworks

PittsburghSeed–Late Stage

AMAJGMJ11 people

Harmonix Fund

La QuintaSeed–Series C

CMDMEPMW7 people

Hillhouse Capital

ChangyangSeed–Series C$500K

TKBWDLHW7 people

Mithril Capital Management

AustinSeries B–Late Stage

PTARAKAR5 people

Valspring Capital

BostonSeries A–Growth

AZASYCCL8 people

Pureos Bioventures

PfäffikonSeed–Series C

DEKBMMVG9 people

Cultivian Sandbox Ventures

ChicagoSeed–Late Stage$5M – $15M

AZBSDPNR8 people

Santen Pharmaceutical

OsakaSeries A–Series C

HIIKJAMP24 people

Roche Venture Fund

BaselSeed–Growth$648K – $3.2M

MSAHCCBF7 people

Heran Partners

AntwerpSeed–Series B

AVHVJMKV13 people

ISA Ventures

Cedar RapidsPre-Seed–Late Stage$25K – $1M

FCCGEESG4 people

Fast Track Initiative

TokyoPre-Seed–Growth

NRKY2 people

Leaps by Bayer

LeverkusenSeed–Growth

BKDDDNPA6 people

Visionary Ventures

Newport BeachSeries A–Growth$5M – $15M

GHDGPSBC9 people

Fine Structures Ventures

CambridgePre-Seed–Late Stage

AJCDDNDM10 people

Redesign Health

New YorkSeed–Late Stage

NGPAAGMK13 people

Luma Group

New YorkSeed–Growth

JFTKJKNM14 people

Triatomic Capital

Palo AltoSeed–Series C$100K – $1M

JHPZSHWV8 people

Esplanade Ventures

TorontoSeed–Series B

SESMESAN10 people

Yuanta Investment

SeoulSeed–Late Stage$1M – $15M

강강김김20 people

Data sourced from public filings and firms' own websites — see our methodology.